Vor Biopharma (NASDAQ:VOR) Trading Up 17.8% – Still a Buy?

Vor Biopharma Inc. (NASDAQ:VOR)’s share price shot up 17.8% during mid-day trading on Thursday . The stock traded as high as $20.32 and last traded at $21.6640. Approximately 288,239 shares traded hands during trading, a decline of 73% from the average daily volume of 1,053,732 shares. The stock had previously closed at $18.39.

Analyst Upgrades and Downgrades

VOR has been the subject of several research reports. Weiss Ratings raised shares of Vor Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. Wedbush boosted their target price on shares of Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a research note on Thursday, May 14th. Wells Fargo & Company initiated coverage on shares of Vor Biopharma in a report on Thursday, March 19th. They set an “overweight” rating and a $30.00 price target for the company. Wall Street Zen cut Vor Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Jefferies Financial Group upgraded Vor Biopharma to a “strong-buy” rating in a research report on Thursday, April 30th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $42.25.

Vor Biopharma Stock Performance

The business’s fifty day moving average price is $14.93 and its 200 day moving average price is $14.57.

Vor Biopharma (NASDAQ:VOR) last posted its quarterly earnings data on Monday, March 30th. The company reported $307.61 earnings per share for the quarter. Research analysts forecast that Vor Biopharma Inc. will post -2.51 EPS for the current year.

Insider Activity at Vor Biopharma

In other news, Director Ra Capital Management, L.P. sold 165,150 shares of the stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $15.77, for a total value of $2,604,415.50. Following the completion of the sale, the director owned 2,402,095 shares of the company’s stock, valued at approximately $37,881,038.15. This represents a 6.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last 90 days, insiders sold 2,742,903 shares of company stock valued at $44,672,376. Insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On Vor Biopharma

A number of hedge funds have recently made changes to their positions in VOR. China Universal Asset Management Co. Ltd. bought a new stake in Vor Biopharma in the fourth quarter valued at approximately $36,000. Bank of America Corp DE raised its holdings in Vor Biopharma by 679.3% during the 3rd quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock worth $232,000 after purchasing an additional 4,144 shares during the last quarter. Squarepoint Ops LLC bought a new position in Vor Biopharma during the 3rd quarter worth approximately $230,000. BNP Paribas Financial Markets raised its holdings in Vor Biopharma by 497.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock worth $296,000 after purchasing an additional 5,058 shares during the last quarter. Finally, Bridgeway Capital Management LLC acquired a new position in shares of Vor Biopharma in the 3rd quarter worth approximately $304,000. 97.29% of the stock is currently owned by institutional investors.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).